11/16
01:50 am
atyr
Is aTyr Pharma, Inc. (ATYR) the Best Multibagger Stock to Buy Heading into 2025? [Yahoo! Finance]
Medium
Report
Is aTyr Pharma, Inc. (ATYR) the Best Multibagger Stock to Buy Heading into 2025? [Yahoo! Finance]
11/15
08:05 am
atyr
aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis [Yahoo! Finance]
Low
Report
aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis [Yahoo! Finance]
11/15
08:00 am
atyr
aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis
Medium
Report
aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis
11/7
04:01 pm
atyr
aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update
Low
Report
aTyr Pharma Announces Third Quarter 2024 Results and Provides Corporate Update
10/31
03:32 pm
atyr
Nearly 350 Patients Participate in the Foundation for Sarcoidosis Research Externally Led Patient-Focused Drug Development Meeting with the FDA [Yahoo! Finance]
Low
Report
Nearly 350 Patients Participate in the Foundation for Sarcoidosis Research Externally Led Patient-Focused Drug Development Meeting with the FDA [Yahoo! Finance]
10/31
08:00 am
atyr
aTyr Pharma to Present at Upcoming Investor Conferences
Medium
Report
aTyr Pharma to Present at Upcoming Investor Conferences
10/29
08:00 am
atyr
Atyr PHARMA INC (NASDAQ: ATYR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
Low
Report
Atyr PHARMA INC (NASDAQ: ATYR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
10/8
08:00 am
atyr
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
Low
Report
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
10/4
07:36 am
atyr
Atyr PHARMA INC (NASDAQ: ATYR) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $17.00 price target on the stock.
Low
Report
Atyr PHARMA INC (NASDAQ: ATYR) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $17.00 price target on the stock.
10/2
08:00 am
atyr
aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
Low
Report
aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
9/9
04:41 am
atyr
aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point [Seeking Alpha]
Low
Report
aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point [Seeking Alpha]
9/5
07:51 am
atyr
Atyr PHARMA INC (NASDAQ: ATYR) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $9.00 price target on the stock.
Medium
Report
Atyr PHARMA INC (NASDAQ: ATYR) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $9.00 price target on the stock.